Colin Vicente

Cost of glaucoma in Canada: analyses based on visual field and physician's assessment.

PurposeA longitudinal, retrospective study investigated the cost of primary open angle glaucoma (POAG). MethodsPatient files from two tertiary care glaucoma practices were reviewed. Patients diagnosed with POAG and ≥2.5 years of follow-up data were included. Data collected included visual field mean deviation, physicians assessment, and resource utilization (physician visits, procedures, and medications). Costs, reported in 2001 Canadian dollars, were compared between groups, based on initial visual field mean deviation, including mild (<5 dB), moderate (5 to <12 dB), and severe (≥12 dB), and based on physicians assessment, including controlled, uncontrolled, or patients initially uncontrolled for 12 months who become controlled. ResultsOf 411 patient charts extracted, 265 were included; 35 were excluded for ocular comorbidities and 111 patients with insufficient follow-up. Mean (standard deviation) yearly costs overall (N = 265) and for mild (n = 90), moderate (n = 91), and severe (n = 84) groups were

Economic evaluation of Avonex® (interferon beta-1a) in patients following a single demyelinating event

508 (

Quality assessment of meta-analyses of RCTs of pharmacotherapy in major depressive disorder

278),

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece.

408 (

Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden

266),

Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: A Canadian analysis

512 (

Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway.

288), and

Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland

609 (

Association between mean intraocular pressure, disease stability and cost of treating glaucoma in Canada

243), respectively. Differences between mean yearly costs were statistically significant for all three groups (P < 0.05). Costs for controlled (n = 110), uncontrolled (n = 76), and uncontrolled then controlled group (n = 79) were

The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada

423 (